The Wilms’ tumor gene-1 is a prognostic factor in myelodysplastic syndrome: a meta analysis

Abstract

Previous studies have suggested that Wilms’ tumor gene-1 (WT1) may be related to a decrease in both relapse-free survival (RFS) and overall survival (OS) for patients with myelodysplastic syndrome (MDS). Therefore, we conducted a meta-analysis on the utility of WT1 as a prognostic indicator of MDS. Published reports were searched in the following databases: Cochrane Library, PubMed, Embase, and Web of Science. The meta-analysis was conducted using the Cochrane Collaboration RevMan 5.2 software. Six publications with 450 total patients met the inclusion criteria and were subjected to further examination. The results showed a reduction in both overall survival (OS) and leukemia-free survival (LFS) with increasing WT1 expression levels: 1-year OS (odds ratio, OR = 0.16; 95% CI = 0.08–0.34, P < 0.001), 3-year OS (OR = 0.21; 95% CI = 0.09–0.47, P < 0.001), 5-year OS (OR = 0.24; 95% CI = 0.06–0.92, P = 0.04), 1-year LFS (OR = 0.06; 95% CI = 0.02–0.18; P < 0.001), 3-year LFS (OR = 0.20; 95% CI = 0.09–0.46; P < 0.001), and 5-year LFS (OR = 0.12; 95% CI = 0.04–0.38; P < 0.001). In terms of patients receiving hematopoietic stem cell transplantation, the cumulative incidence of relapse (CIR) was higher in the WT1 over-expression group than in the low-expression group: 1-year CIR (OR = 13.69; 95% CI = 2.99–62.62; P < 0.001), 3-year CIR (OR = 6.52; 95% CI = 2.31–18.40, P < 0.001). In conclusion, WT1 over-expression is a prognostic factor for MDS.

Peripheral blood marker of residual acute leukemia after hematopoietic cell transplantation using multi-plex digital droplet PCR

“…Several of our patients who progressed demonstrated an increased number of TAA antigens number over time. This was not unexpected since these TAA encode for anti-apoptotic proteins, which would confer a leukemia survival advantage ( 32 , 33 , 36 , 37 , 44 , 51 , 57 , 70 ).…”

DNA methylation identifies genetically and prognostically distinct subtypes of myelodysplastic syndromes

“…This is consistent with prior work that has associated WT1 expression with poor prognosis in MDS and AML. [63][64][65][66] More novel was the association between shorter OS and CD93 hypomethylation in our cohort and overexpression in an external MDS cohort, because CD93 is a transmembrane receptor implicated in the pathogenesis of several malignancies. [67][68][69] The role of CD93 in myeloid malignancies is relatively unknown.…”

Role of PARP1-mediated autophagy in EGFR-TKI resistance in non-small cell lung cancer

“…TKIs combined with radiotherapy or other conventional cancer therapies do not improve prognosis 3 . Different strategies have been suggested to overcome this resistance, such as combining TKIs with thermal therapy 4 , anti-angiogenic agents 5 , 6 , or c-Met inhibitors 7 . These strategies seem to improve prognosis, but the results are far from perfect.…”